📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Elexacaftor-Tezacaftor-Ivacaftor improve Gastro-Oesophageal reflux and Sinonasal symptoms in advanced cystic fibrosis. (2022)

First Author: Shakir S

Attributed to: Investigation into the role of ceramide in the pathogenesis of cystic fibrosis lung disease funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.jcf.2022.06.003

PubMed Identifier: 35718668

Publication URI: http://europepmc.org/abstract/MED/35718668

Type: Journal Article/Review

Volume: 21

Parent Publication: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Issue: 5

ISSN: 1569-1993